MRI Compatible MS2 Nanoparticles Designed to Cross the Blood-Brain-Barrier: Providing a Path towards Tinnitus Treatment.

MRI Compatible MS2 Nanoparticles Designed to Cross the Blood-Brain-Barrier: Providing a Path towards Tinnitus Treatment.

Nanomedicine. 2018 Apr 14;:

Authors: Apawu AK, Curley SM, Dixon AR, Hali M, Sinan M, Braun RD, Castracane J, Cacace AT, Bergkvist M, Holt AG

Abstract
Fundamental challenges of targeting specific brain regions for treatment using pharmacotherapeutic nanoparticle (NP) carriers include circumventing the blood-brain-barrier (BBB) and tracking delivery. Angiopep-2 (AP2) has been shown to facilitate the transport of large macromolecules and synthetic nanoparticles across the BBB. Thus, conjugation of AP2 to an MS2 bacteriophage based NP should also permit transport across the BBB. We have fabricated and tested a novel MS2 capsid-based NP conjugated to the ligand AP2. The reaction efficiency was determined to be over 70%, with up to two angiopep-2 conjugated per MS2 capsid protein. When linked with a porphyrin ring, manganese (Mn2+) remained stable within MS2 and was MRI detectable. Nanoparticles were introduced intracerebroventricularly or systemically. Systemic delivery yielded dose dependent, non-toxic accumulation of NPs in the midbrain. Design of a multifunctional MRI compatible NP platform provides a significant step forward for the diagnosis and treatment of intractable brain conditions, such as tinnitus.

PMID: 29665440 [PubMed - as supplied by publisher]

https://ift.tt/2HKlUTp